These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20037446)

  • 21. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer.
    Saito K; Isayama H; Sakamoto Y; Nakai Y; Ishigaki K; Tanaka M; Watadani T; Arita J; Takahara N; Mizuno S; Kogure H; Ijichi H; Tateishi K; Tada M; Hasegawa K; Fukayama M; Kokudo N; Koike K
    Med Oncol; 2018 May; 35(7):100. PubMed ID: 29846849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
    Yamauchi J; Kanai M; Matsumoto S; Nishimura T; Yazumi S; Kami K; Kawaguchi Y; Yasuda H; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Fukushima M; Doi R; Chiba T
    Pancreas; 2008 Apr; 36(3):327-8. PubMed ID: 18362852
    [No Abstract]   [Full Text] [Related]  

  • 23. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
    Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
    Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakagawa N; Ohge H; Sueda T
    Am J Surg; 2008 Jun; 195(6):757-62. PubMed ID: 18367131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
    Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
    Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
    Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-Term Survival Due to Combination Therapy in a Patient with Locally Advanced Body-Tail Pancreatic Cancer].
    Ueda N; Fujii Y; Miura S; Fujita J; Tomita Y; Ohnishi T; Fujita H; Kinami S; Omote K; Nakano Y; Kosaka T; Motoo Y
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1373-1375. PubMed ID: 29394638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A Case of Pancreatic Head Cancer Treated with Pancreaticoduodenectomy Combined with Hepatic Artery Resection Following Neoadjuvant Chemotherapy].
    Maeda S; Takano S; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Kagawa S; Miyazaki M
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2370-2. PubMed ID: 26805367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
    J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of curatively resected locally advanced cancer of the pancreatic body treated by distal pancreatectomy with en bloc celiac axis resection after neoadjuvant chemotherapy].
    Okada T; Sakurai N; Yamamoto K; Motoi F; Kakizaki Y; Tamura G; Unno M; Iizawa H
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):135-7. PubMed ID: 22241369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
    Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Okada K; Takahashi S; Sueda T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):801-811. PubMed ID: 28314992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
    Wada K; Sano K; Amano H; Miura F; Toyota N; Ito H; Shibuya M; Ikeda Y; Kainuma M; Takada T
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):692-8. PubMed ID: 26136371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
    Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
    Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of pancreatic cancer with celiac trunk and common hepatic artery invasion successfully resected after gemcitabine+S-1therapy].
    Katoh R; Takeyoshi I; Sunose Y; Yoshinari D; Totsuka O; Toya H; Ogawa H; Hirai K
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):273-5. PubMed ID: 22333642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
    Kobayashi S; Honda G; Kurata M; Okuda Y; Sakamoto K; Karasawa K; Chang T; Egawa N; Kamisawa T; Omuro Y; Tsuruta K
    Hepatogastroenterology; 2015 Jun; 62(140):1031-6. PubMed ID: 26902051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer].
    Nakayama A; Tajima H; Kitagawa H; Shoji M; Nakanuma S; Makino I; Hayashi H; Nakagawara H; Miyashita T; Takamura H; Ohta T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2205-7. PubMed ID: 25731471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
    Yoshida Y; Sugawara N; Minami T; Iwata N; Ikeda K; Endoh T; Sasano H
    Nihon Shokakibyo Gakkai Zasshi; 2013 Apr; 110(4):660-8. PubMed ID: 23558130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current status and future directions of chemotherapy for pancreatic cancer].
    Furuse J
    Nihon Shokakibyo Gakkai Zasshi; 2013 Dec; 110(12):2060-5. PubMed ID: 24305093
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.